Is Kazia Therapeutics Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Kazia Therapeutics Ltd (KZIA) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Kazia Therapeutics Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Kazia Therapeutics Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Kazia Therapeutics Ltd?

Muslim investors may consider investing in Kazia Therapeutics Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Kazia Therapeutics Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of Kazia Therapeutics Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Kazia Therapeutics Ltd updated?

The Shariah compliance status of Kazia Therapeutics Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Kazia Therapeutics Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Kazia Therapeutics Ltd?

You can check the latest Shariah compliance status of Kazia Therapeutics Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

KZIA Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 20, 2026

Report Source: 2026 2nd Quarter Report

Kazia Therapeutics Ltd. Stock Analysis KZIA

United States Health Care Micro Cap Report: Q2, 2026

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. The company is headquartered in Sydney, New South Wales. The firm operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. The company is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. The company designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.

Key Statistics of Kazia Therapeutics Ltd (KZIA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$13.16$13.93

Today's Open

$13.51

Volume

165.35K

P/E Ratio (TTM)

52 Week Range

$3.22$17.40

Market Cap

145.55M

Avg. Volume

278.87K

Dividend Yield

Financial Metrics & Statements of Kazia Therapeutics Ltd (KZIA)

FAQ's for Kazia Therapeutics Ltd (KZIA)

According to Musaffa’s Shariah screening methodology, Kazia Therapeutics Ltd (KZIA) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.